Non-Insured Health Benefits (NIHB) Program
TAKHZYRO is covered by the Non-Insured Health Benefits (NIHB) Program provided patient meets coverage criteria
Eligibility
For TAKHZYRO to be eligible for coverage by the NIHB Program, prescribers must submit a limited use benefit request form and approval must be in place before the patient fills the prescription. Deductibles may apply. For more information concerning the reimbursement process, contact OnePath®.
Reimbursement Criteria
We are pleased to inform you that TAKHZYRO (lanadelumab injection) is reimbursed in Nunavut for your hereditary angioedema (HAE) patients who meet the following criteria:
For the routine prevention of attacks of HAE in adolescents and adults.
Criteria for initial 3‑month coverage
- Patient is at least 12 years of age.
- Prescribed by a specialist physician who has experience in the diagnosis of HAE in patients.
- Patient has experienced at least three HAE attacks that required the use of an acute injectable treatment within any four-week period before initiating lanadelumab or another long-term prophylaxis (LTP) (for those who are already receiving LTP and intend to transition to lanadelumab).
Initial response assessment (after three months of therapy with lanadelumab)
- Reduction in the number of HAE attacks for which acute injectable treatment was received compared to the rate of attacks prior to initiating treatment with lanadelumab or another LTP treatment (for those who were on another LTP treatment and transitioned to lanadelumab).
Continued coverage (at 6 months and thereafter)
- Continued response, defined as no increase in the number of HAE attacks for which acute injectable treatment was received compared to the number of attacks prior to initiating treatment with lanadelumab or another LTP treatment (for those who were on another LTP treatment and transitioned to lanadelumab).
Lanadelumab should not be used in combination with other medications used LTP treatment of angioedema (e.g., C1 esterase inhibitor).
Coverage is provided for a maximum dose of 300 mg every two weeks.
